32,737 Shares in Arcellx, Inc. (NASDAQ:ACLX) Bought by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC purchased a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 32,737 shares of the company's stock, valued at approximately $2,511,000. Schonfeld Strategic Advisors LLC owned 0.06% of Arcellx as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcellx by 9.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,836 shares of the company's stock valued at $754,000 after purchasing an additional 858 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Arcellx by 156.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company's stock worth $23,400,000 after acquiring an additional 186,013 shares during the period. Gilead Sciences Inc. purchased a new position in Arcellx during the fourth quarter worth about $515,418,000. Swiss National Bank lifted its position in Arcellx by 0.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the company's stock valued at $4,862,000 after purchasing an additional 500 shares during the period. Finally, Wells Fargo & Company MN increased its position in Arcellx by 35.7% during the 4th quarter. Wells Fargo & Company MN now owns 26,638 shares of the company's stock worth $2,043,000 after purchasing an additional 7,002 shares during the period. Hedge funds and other institutional investors own 96.03% of the company's stock.

Arcellx Stock Up 6.7 %

ACLX stock traded up $3.53 on Thursday, reaching $56.47. 1,260,517 shares of the company's stock were exchanged, compared to its average volume of 575,048. Arcellx, Inc. has a twelve month low of $47.86 and a twelve month high of $107.37. The firm has a market cap of $3.11 billion, a PE ratio of -79.53 and a beta of 0.34. The stock has a fifty day moving average of $64.58 and a 200-day moving average of $73.26.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.29). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. On average, equities research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Insider Activity at Arcellx

In other Arcellx news, insider Rami Elghandour sold 38,300 shares of Arcellx stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total value of $2,375,366.00. Following the transaction, the insider now owns 149,186 shares in the company, valued at $9,252,515.72. This trade represents a 20.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kavita Patel sold 1,500 shares of the business's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $64.20, for a total transaction of $96,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 54,455 shares of company stock valued at $3,407,903 over the last quarter. Insiders own 6.24% of the company's stock.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).